Cancer Research Meeting Calendar  Telomeres
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 52, 3886-3891, July 15, 1992]
© 1992 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kucera, G. L.
Right arrow Articles by Capizzi, R. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kucera, G. L.
Right arrow Articles by Capizzi, R. L.

1-ß-D-Arabinofuranosylcytosine-diphosphate-choline Is Formed by the Reversal of Cholinephosphotransferase and not via Cytidylyltransferase1

Gregory L. Kucera2 and Robert L. Capizzi3

Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina 27157

In an effort to identify the pathway leading to the formation of 1-ß-D-arabinofuranosylcytosine-diphosphate (ara-CDP)-choline from 1-ß-D-arabinofuranosylcytosine (ara-C) treatment of cultured cells, as well as of cells obtained from leukemia patients, we probed the enzymatic steps involved in the CDP-choline pathway for phosphatidylcholine biosynthesis. Ara-C-triphosphate was not a substrate for CTP:phosphocholine cytidylyltransferase activity under the conditions employed, whereas CTP and dCTP were utilized to form CDP-choline and dCDP-choline, respectively. When presented together, ara-C-triphosphate and CTP inhibited the enzymatic conversion of CTP to CDP-choline in the presence of phosphocholine, with a Ki of 6 mM.

Since CTP:phosphocholine cytidylytransferase did not appear to be responsible for the increased levels of area-CDP-choline, we next studied the other enzyme in the pathway for phosphatidylcholine synthesis that could form ara-CDP-choline, CDP-choline:1,2-diacylglycerol cholinephosphotransferase. CDP-choline:1,2-diacylglycerol cholinephosphotransferase activity present in microsomes isolated from L5178Y murine leukemia cells exhibited a reversal of its normal catalytic activity, using CMP and 1-ß-D-arabinofuranosylcytosine-monophosphate (ara-CMP) along with phosphatidylcholine to produce either CDP-choline or ara-CDP-choline, plus diradylglycerol. The Vmax and Km values for CMP were 0.78 ± 0.04 nmol/min/mg and 340 ± 20 µM, respectively, whereas the Vmax and Km for ara-CMP were 0.22 ± 0.06 nmol/min/mg and 1410 ± 540 µM, respectively. A Ki value of 3 mM was obtained for ara-CMP under the cell-free assay conditions used. These results indicate that ara-CDP-choline most likely arises from a reversal of the CDP-choline:1,2-diacylglycerol cholinephosphotransferase utilizing ara-CMP, rather than from the catalysis of ara-C-triphosphate plus phosphocholine to ara-CDP-choline by CTP:phosphocholine cytidylyltransferase. It is speculated that this mechanism may explain, in part, the rapid cellular lysis observed with high dose ara-C therapy.

1 This work was supported by grants from the American Cancer Society (CH471N), the Cancer Services, Inc., the Gaston County Cancer Society, Inc., and the Comprehensive Cancer Center of Wake Forest University Core Grant NIH NCI CA 12197.

2 To whom requests for reprints should be addressed.

3 Present address: U.S. Bioscience, One Tower Bridge, 100 Front Street, P.O. Box 851, West Conshohocken, PA 19428.

Received 2/ 3/92. Accepted 5/ 4/92.




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
C. R. Johnson, J. Chun, R. Bittman, and W. D. Jarvis
Intrinsic Cytotoxicity and Chemomodulatory Actions of Novel Phenethylisothiocyanate Sphingoid Base Derivatives in HL-60 Human Promyelocytic Leukemia Cells
J. Pharmacol. Exp. Ther., May 1, 2004; 309(2): 452 - 461.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
E. S. HO, D. C. LIN, D. B. MENDEL, and T. CIHLAR
Cytotoxicity of Antiviral Nucleotides Adefovir and Cidofovir Is Induced by the Expression of Human Renal Organic Anion Transporter 1
J. Am. Soc. Nephrol., March 1, 2000; 11(3): 383 - 393.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. O. Rodriguez Jr. and V. Gandhi
Arabinosylguanine-induced Apoptosis of T-Lymphoblastic Cells: Incorporation into DNA Is a Necessary Step
Cancer Res., October 1, 1999; 59(19): 4937 - 4943.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
W. D. Jarvis, F. A. Fornari Jr., R. M. Tombes, R. K. Erukulla, R. Bittman, G. K. Schwartz, P. Dent, and S. Grant
Evidence for Involvement of Mitogen-Activated Protein Kinase, Rather than Stress-Activated Protein Kinase, in Potentiation of 1-beta -D-Arabinofuranosylcytosine-Induced Apoptosis by Interruption of Protein Kinase C Signaling
Mol. Pharmacol., November 1, 1998; 54(5): 844 - 856.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
S. P. Whitman, F. Civoli, and L. W. Daniel
Protein Kinase Cbeta II Activation by 1-beta -D-Arabinofuranosylcytosine Is Antagonistic to Stimulation of Apoptosis and Bcl-2alpha Down-regulation
J. Biol. Chem., September 19, 1997; 272(38): 23481 - 23484.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1992 by the American Association for Cancer Research.